Therefore, blocking the PD-1/PD-L1 pathway in the bone marrow microenvironment with drugs alone or in combination with other therapeutic regimens offers new therapeutic ideas for MM, and has yielded many gains in recent years of intensive research. The gene discussed is PDCD1; the disease is Miyoshi myopathy.